candesartan has been researched along with Hypertension, Essential in 10 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Three hundred sixty-two individuals were screened, and 290 patients aged 19 to 75 years with mild to moderate hypertension (diastolic blood pressure [DBP], 90-110 mm Hg) were randomly assigned to 60 to 120 mg/d of fimasartan or 8 mg/d of candesartan after a 2-week placebo run-in period." | 9.22 | A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension. ( Cha, GS; Cha, TJ; Chae, SC; Chun, KJ; Hong, GR; Hur, SH; Hwang, JY; Kim, DI; Kim, DS; Kim, KS; Kim, MH; Lee, JH; Lee, SG; Yang, DH, 2016) |
| "The objective of this study was to investigate the efficacy of the fixed-dose combination olmesartan/amlodipine 40/10 mg in patients with moderate essential hypertension not controlled on candesartan 32 mg." | 9.19 | Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2014) |
| "A direct switch of candesartan to the fixed-dose combination olmesartan/amlodipine in uncontrolled hypertension is a frequent clinical requirement but is not covered by current labeling." | 9.17 | Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2013) |
| "The comparison of antihypertensive effects between telmisartan and candesartan in patients with essential hypertension has been investigated in several small studies." | 9.01 | A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension. ( Dong, P; Liu, H; Zhao, D, 2019) |
| "This study investigated whether the angiotensin II type-1 receptor blocker (ARB) candesartan affects markers of oxidative stress in type 2 diabetes mellitus (DM) patients with essential hypertension (EH)." | 7.79 | Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. ( Miura, Y; Mizuno, K; Ono, Y; Takahashi, M; Watanabe, T, 2013) |
| " Three hundred sixty-two individuals were screened, and 290 patients aged 19 to 75 years with mild to moderate hypertension (diastolic blood pressure [DBP], 90-110 mm Hg) were randomly assigned to 60 to 120 mg/d of fimasartan or 8 mg/d of candesartan after a 2-week placebo run-in period." | 5.22 | A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension. ( Cha, GS; Cha, TJ; Chae, SC; Chun, KJ; Hong, GR; Hur, SH; Hwang, JY; Kim, DI; Kim, DS; Kim, KS; Kim, MH; Lee, JH; Lee, SG; Yang, DH, 2016) |
| " The Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study is a double-blind, placebo-controlled cross-over study where each subject received amlodipine, bisoprolol,hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order." | 5.20 | Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs. ( Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Donner, KM; Frau, F; Glorioso, N; Glorioso, V; Gong, Y; Gums, JG; Hiltunen, TP; Johnson, JA; Kontula, KK; Ripatti, S; Saarela, J; Salvi, E; Sarin, AP; Turner, ST; Zaninello, R, 2015) |
| "The objective of this study was to investigate the efficacy of the fixed-dose combination olmesartan/amlodipine 40/10 mg in patients with moderate essential hypertension not controlled on candesartan 32 mg." | 5.19 | Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2014) |
| "A direct switch of candesartan to the fixed-dose combination olmesartan/amlodipine in uncontrolled hypertension is a frequent clinical requirement but is not covered by current labeling." | 5.17 | Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2013) |
| "The comparison of antihypertensive effects between telmisartan and candesartan in patients with essential hypertension has been investigated in several small studies." | 5.01 | A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension. ( Dong, P; Liu, H; Zhao, D, 2019) |
| "This study investigated whether the angiotensin II type-1 receptor blocker (ARB) candesartan affects markers of oxidative stress in type 2 diabetes mellitus (DM) patients with essential hypertension (EH)." | 3.79 | Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. ( Miura, Y; Mizuno, K; Ono, Y; Takahashi, M; Watanabe, T, 2013) |
| "Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels." | 1.43 | Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, D | 1 |
| Liu, H | 1 |
| Dong, P | 1 |
| Zemmrich, C | 2 |
| Lüders, S | 2 |
| Gansz, A | 2 |
| Sturm, CD | 2 |
| Fimmers, R | 2 |
| Nadal, J | 2 |
| Schmieder, RE | 2 |
| Schrader, J | 2 |
| Bramlage, P | 2 |
| Ono, Y | 1 |
| Mizuno, K | 1 |
| Takahashi, M | 1 |
| Miura, Y | 1 |
| Watanabe, T | 1 |
| Rakugi, H | 1 |
| Kario, K | 1 |
| Enya, K | 1 |
| Sugiura, K | 1 |
| Ikeda, Y | 1 |
| Hiltunen, TP | 1 |
| Donner, KM | 1 |
| Sarin, AP | 1 |
| Saarela, J | 1 |
| Ripatti, S | 1 |
| Chapman, AB | 1 |
| Gums, JG | 1 |
| Gong, Y | 1 |
| Cooper-DeHoff, RM | 1 |
| Frau, F | 1 |
| Glorioso, V | 1 |
| Zaninello, R | 1 |
| Salvi, E | 1 |
| Glorioso, N | 1 |
| Boerwinkle, E | 1 |
| Turner, ST | 1 |
| Johnson, JA | 1 |
| Kontula, KK | 1 |
| Wang, Z | 1 |
| Zeng, C | 1 |
| Villar, VA | 1 |
| Chen, SY | 1 |
| Konkalmatt, P | 1 |
| Wang, X | 1 |
| Asico, LD | 1 |
| Jones, JE | 1 |
| Yang, Y | 1 |
| Sanada, H | 1 |
| Felder, RA | 1 |
| Eisner, GM | 1 |
| Weir, MR | 1 |
| Armando, I | 1 |
| Jose, PA | 1 |
| Skoczylas, A | 1 |
| Piecha, G | 1 |
| Więcek, A | 1 |
| Lee, JH | 1 |
| Yang, DH | 1 |
| Hwang, JY | 1 |
| Hur, SH | 1 |
| Cha, TJ | 1 |
| Kim, KS | 1 |
| Kim, MH | 1 |
| Chun, KJ | 1 |
| Cha, GS | 1 |
| Hong, GR | 1 |
| Lee, SG | 1 |
| Kim, DS | 1 |
| Kim, DI | 1 |
| Chae, SC | 1 |
| Buda, V | 1 |
| Andor, M | 1 |
| Cristescu, C | 1 |
| Voicu, M | 1 |
| Cochera, F | 1 |
| Tuduce, P | 1 |
| Petrescu, L | 1 |
| Tomescu, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension[NCT03276598] | Phase 4 | 233 participants (Actual) | Interventional | 1999-11-25 | Completed | ||
| A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb)[NCT01135212] | Phase 3 | 290 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan and Hypertension, Essential
| Article | Year |
|---|---|
A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Essential Hypertension; | 2019 |
5 trials available for candesartan and Hypertension, Essential
4 other studies available for candesartan and Hypertension, Essential
| Article | Year |
|---|---|
Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; B | 2013 |
Human GRK4γ142V Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2016 |
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; | 2016 |
The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; C-Reactive Protein; Cross-Sectional Stu | 2017 |